This is a nice summary by the Pharmalot blog (via Deloitte) indicating where biopharma dealmaking occurred last year relative to disease areas. Not surprisingly, cancer was in the number one slot with 161 deals and represented nearly 25% of the total. More than half the deals were signed during the discovery or pre-clinical phases.
Median deal sizes (at least those disclosed) were higher in areas other than cancer -- autoimmune and inflammatory -- followed by endocrine and metabolic -- were one and two. Not surprisingly, upfront payments rose in alignment with phase in the pipeline. Phase I earned median payments $8.4 million, phase II $19.5 million and phase III $25 million. Registration stage compounds were more than double that at $59 million.
The five largest deals (out of 714 total) had an announced aggregate value of $8.2 billion with upfront payments totaling $738 million. So now you know where the money went, will it keep going there in coming years?
Posted by Bruce Lehr May 31st 2012.